MHRA Grants Marketing Authorisation for Global Blood Therapeutics’s Oxbryta (Voxelotor)
Summary: Voxelotor is the first medicine in Britain to directly inhibit sickle haemoglobin polymerisation Global Blood Therapeutics (GBT) has announced that the…
Summary: Voxelotor is the first medicine in Britain to directly inhibit sickle haemoglobin polymerisation Global Blood Therapeutics (GBT) has announced that the…
Summary : Institute for Cancer Research highlights missed opportunity for NICE to reform its cancer drug assessment processes National Institute for Health…
Synopsis – England’s National Institute for Health and Care Excellence (NICE) has given a thumbs up to Sobi’s paroxysmal nocturnal hemoglobinuria (PNH)…
Key Points – SMC approved Combination of Opdivo (Nivolumab) plus Cabometryx (Cabozantinib) for treatment of Advanced Renal Carcinoma In a Phase III…